Anti-Malarial drugs Market

Anti-Malarial Drugs Market Overview (2022 to 2032)

The global anti-malarial drugs market was valued at around US$ 948.5 Million at the end of 2021. The market is projected to register a 4.8% CAGR and top a valuation of US$ 1515.8 Million by 2032.

Due to increased research for novel medications and new combination therapies the anti-malarial drugs market is set to experience significant revenue growth in the coming times.

Malaria is a contagious illness that spreads when a female Anopheles mosquito bites a host, allowing parasites to enter the body. Fever, exhaustion, nausea, and headaches are additional symptoms brought on by the destruction of red blood cells by merozoites, which also proliferate inside them. Antimalarial drugs are those that are used to treat and ward against malaria infections. Several drugs are available in the market for the treatment of malarial infection such as quinine, chloroquine, proguanil, mefloquine, and pyrimethamine.

Attributes	Details
Anti-Malarial Drugs Market Value in 2021	USD 948.5 Million
Anti-Malarial Drugs Market Value in 2032	USD 1515.8 Million
Anti-Malarial Drugs Market CAGR (2022 to 2032)	4.8%

What are the Major Drivers Boosting the Demand for Anti-Malarial Drugs Market?

The high prevalence of malaria in affected nations increased public awareness due to government initiatives to reduce the prevalence rate of malaria by conducting various campaigns for spreading awareness about the prevention of malaria, and increased research for the development of novel drugs and new combination therapies, among other things, are the factors that are driving the growth of anti-malarial drugs market.

One of the aspects driving the market's development is the rise in the incidence of traveler’s malaria. Numerous tourists from around the world visit malaria-infected nations each year, which is predicted to raise the risk of disease.

Strong efforts made by various regional and international governments and regulating agencies, including the USA Food and Drug Administration (FDA), to reduce the prevalence of the malarial disease worldwide are also seen to be a major driver of the market for anti-malarial drugs. Other key elements fueling the expansion of the global market for anti-malarial drugs are the presence of significant players, improved Research and Development facilities, and healthcare expenditure.

Which Region Shows Strong Growth Potential in the Anti-Malarial Drugs Market?

The anti-malarial drugs market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

Africa is the leading region in the global anti-malarial drugs market owing to the high prevalence of malarial infection in various nations in the region and various healthcare facilities provided by global health agencies.

Increasing regulatory approval of the medications and the presence of major pharmaceutical companies are predicted to contribute to the lucrative development of the anti-malarial drug market in East Asia in the coming years.

The South American region is also predicted to show lucrative growth due to increasing awareness regarding the use of anti-malaria drugs for the early diagnosis of malarial disease.

Who are the Key Players in the Anti-Malarial Drugs Market?

Alvizia Healthcare Pvt. Ltd., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Ipca Laboratories Ltd., Merck & Co., Inc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories), Zydus Cadila, Lincoln Pharmaceuticals, Strides Pharma Science, Glenmark Pharmaceuticals, Alliance Pharmaceuticals.

Scope of Report

Report Attributes	Details
Growth Rate	CAGR of 4.8% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2012 to 2021
Forecast Period	2022 to 2032
Qualitative Units	Revenue in USD Million, and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segment Covered	Malaria Type Drug Class Route of Administration Distribution Channel Region
Region Covered	North America Latin America Europe East Asia South Asia Oceania Middle East & Africa
Key Countries Profiled	USA Canada Brazil Mexico Germany United Kingdom France Spain Italy China Japan South Korea Malaysia Singapore Australia New Zealand GCC Countries South Africa Israel
Key Players	Alvizia Healthcare Pvt. Ltd. Bayer AG F. Hoffmann-La Roche Ltd GlaxoSmithKline Plc Ipca Laboratories Ltd. Merck & Co., Inc Novartis AG Pfizer Inc. Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories) Zydus Cadila Lincoln Pharmaceuticals Strides Pharma Science Glenmark Pharmaceuticals Alliance Pharmaceuticals
Customization	Available Upon Request

Key Segments Covered in the Anti-Malarial Drugs Market Report

By Malaria Type:

• Plasmodium Falciparum
• Plasmodium Vivax
• Plasmodium malaria
• Plasmodium ovale

By Drug Class:

• Quinine
• Chloroquine
• Proguanil
• Mefloquine
• Pyrimethamine
• Others

By Route of Administration:

• Oral
• Injectable

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• E-Commerce
• Others

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa (MEA)